|
|
Home > Healthcare > Pharmaceutical > Drug Discovery
Rethinking Pharmaceutical R&D: Will New Strategies Yield a Pipeline Payoff?
|
| Published Date:
September 2009
Published By:
Decision Resources
Page Count:
24
Order Code:
R55-678
|
|
|
|
Introduction
Can radical changes to the structures and strategies of pharmaceutical R&D operations—such as
creating more entrepreneurial environments modeled upon biotech companies—increase their productivity?
Many major companies are reorganizing the research branches of their businesses and fi nding
creative ways to partner with biotech companies and with each other to access or acquire promising
technologies and pipelines. Their goal is to reinvigorate R&D and combat the effects of patent expirations,
generics competition, and other industry pressures.
Questions Answered in This Report
- In recent years, drug developers have invested heavily in various R&D technologies. Is this investment
increasing R&D productivity? What technology strategies are most promising? What
new approaches are pharmaceutical companies using to access enabling technologies for drug
discovery?
- Pharmaceutical companies are seeking to reinvigorate R&D organizations to improve productivity.
What steps are leading companies taking to change R&D? What structures and strategies
have already been implemented within Big Pharma R&D organizations? Can pharmaceutical
companies replicate the innovation of biotech companies by reforming R&D?
- Biotech companies are an important source of novel technologies and drug candidates. How do acquisitions
of and collaborations with biotech companies fi t into Big Pharma’s R&D strategies?
How can companies use business development activities to build up technological capabilities
and pipelines?
- Several Big Pharma companies are charting new territory in early-stage pharma-pharma dealmaking.
Which companies have recently formed innovative partnerships that include early-stage
development? What are the key features of these arrangements? How do these ventures meet
the strategic needs of both partners?
Scope
- Technology strategies: Use of high-throughput technologies and R&D productivity, biologics
platforms, pharma-pharma ventures for enabling technology development.
- Organizational structures and strategies: Restructuring R&D, emulating biotech, case
studies of R&D reorganization.
- Building R&D through business development: M&As, collaborations, R&D strategies.
- Pharma-pharma partnering: Strategic alliances among Big Pharma companies, Phase I
codevelopment collaboration, therapeutic area joint venture.
- Outsourcing R&D: China, India, potential advantages and disadvantages.
- Outlook for pharmaceutical R&D: Changing business models, personalized medicine,
pursuing novel targets, collaboration, high-throughput strategies, translational medicine.
|
Similar Products
• Prostate Cancer Drug Discoveries: What the Future Holds
Published Nov 2009 by Espicom Healthcare Intelligence
• Competitor Analysis: TGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: Thrombopoiesis-Stimulating Agents (TPO)
Published Nov 2009 by La Merie S.L.
• Competitor Analysis: FGF-R Agonists and Antagonists
Published Nov 2009 by La Merie S.L.
• Canada's Pharmaceutical Industry - Porter’s Five Forces Strategy Analysis
Published Nov 2009 by Aruvian's R'search
• Competitor Analysis: FSH, hCG and LH - Therapeutic Proteins for Assisted Reproductive Technology (ART)
Published Nov 2009 by La Merie S.L.
• BI for Drug Development: Oracle Introduces Clinical Development Analytics
Published Nov 2009 by IDC
• CDK Inhibitors Patent Landscape 2009
Published Oct 2009 by France Innovation Scientifique et Transfer
• Protein Kinase Therapeutics in Oncology - Where to Commercialize?
Published Oct 2009 by BioSeeker Group AB
• Antidiabetics in Australia Market Forecast
Published Oct 2009 by Datamonitor
|
|
|
|
0 items
